Chemoinformaics analysis of 2-Bromotetradecane
| Molecular Weight | 277.29 | nRot | 11 |
| Heavy Atom Molecular Weight | 248.058 | nRig | 21 |
| Exact Molecular Weight | 276.145 | nRing | 0 |
| Solubility: LogS | -6.966 | nHRing | 0 |
| Solubility: LogP | 7.384 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 44 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 15 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 29 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 14 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 0 |
| nHA | 0 | APOL | 45.767 |
| nHD | 0 | BPOL | 30.473 |
| QED | 0.439 |
| Synth | 4.498 |
| Natural Product Likeliness | 2.837 |
| NR-PPAR-gamma | 0.024 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.528 |
| Pgp-sub | 0 |
| HIA | 0.005 |
| CACO-2 | -4.742 |
| MDCK | 0.00000843 |
| BBB | 0.864 |
| PPB | 0.989865 |
| VDSS | 2.322 |
| FU | 0.0147791 |
| CYP1A2-inh | 0.076 |
| CYP1A2-sub | 0.558 |
| CYP2c19-inh | 0.076 |
| CYP2c19-sub | 0.942 |
| CYP2c9-inh | 0.13 |
| CYP2c9-sub | 0.417 |
| CYP2d6-inh | 0.013 |
| CYP2d6-sub | 0.887 |
| CYP3a4-inh | 0.275 |
| CYP3a4-sub | 0.625 |
| CL | 15.227 |
| T12 | 0.013 |
| hERG | 0.051 |
| Ames | 0.022 |
| ROA | 0.024 |
| SkinSen | 0.062 |
| Carcinogencity | 0.11 |
| EI | 0.009 |
| Respiratory | 0.681 |
| NR-Aromatase | 0.063 |
| Antiviral | Yes |
| Prediction | 0.803181 |